Synapse - Michael Morris

Results (583)

Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod

Meeting Abstract

Armstrong, A. J.; Kaboteh, R.; Carducci, M. A.; Damber, J. E.; Stadler, W. M.; Mats, H.; Edenbrandt, L.; Forsberg, G.; Nordle, O.; Pili, R.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)

Meeting Abstract

Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer

Meeting Abstract

Halabi, S.; Lin, C. Y.; Kelly, W. K.; Fizazi, K.; Moul, J. W.; Kaplan, E.; Morris, M. J.; Small, E. J.
European Journal of Cancer (2013)

Fulltext@MSK | Save

Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure

Journal Article

Autio, K. A.; Bennett, A. V.; Jia, X.; Fruscione, M.; Beer, T. M.; George, D. J.; Carducci, M. A.; Logothetis, C. J.; Kane, R. C.; Sit, L.; more...
Journal of Oncology Practice (2013)

Fulltext@MSK | Save

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer

Journal Article

Rathkopf, D. E.; Morris, M. J.; Fox, J. J.; Danila, D. C.; Slovin, S. F.; Hager, J. H.; Rix, P. J.; Chow-Maneval, E.; Chen, I.; Gonen, M.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial

Journal Article

Araujo, J. C.; Trudel, G. C.; Saad, F.; Armstrong, A. J.; Yu, E. Y.; Bellmunt, J.; Wilding, G.; McCaffrey, J.; Serrano, S. V.; Matveev, V. B.; more...
Lancet Oncology (2013)

Fulltext@MSK | Save

Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer

Journal Article

Tagawa, S. T.; Milowsky, M. I.; Morris, M.; Vallabhajosula, S.; Christos, P.; Akhtar, N. H.; Osborne, J.; Goldsmith, S. J.; Larson, S.; Taskar, N. P.; more...
Clinical Cancer Research (2013)

Fulltext@MSK | Save

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: Results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)

Journal Article

Aggarwal, R.; Halabi, S.; Kelly, W. K.; George, D.; Mahoney, J. F.; Millard, F.; Stadler, W. M.; Morris, M. J.; Kantoff, P.; Monk, J. P.; more...
Cancer (2013)

Fulltext@MSK | Save

Repetitively dosed docetaxel and 153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer

Journal Article

Autio, K. A.; Pandit-Taskar, N.; Carrasquillo, J. A.; Stephenson, R. D.; Slovin, S. F.; Rathkopf, D. E.; Hong, C.; Heller, G.; Scher, H. I.; Larson, S. M.; more...
Cancer (2013)

Fulltext@MSK | Save

Phase i pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

Journal Article

Carrasquillo, J. A.; O'Donoghue, J. A.; Pandit-Taskar, N.; Humm, J. L.; Rathkopf, D. E.; Slovin, S. F.; Williamson, M. J.; Lacuna, K.; Aksnes, A. K.; Larson, S. M.; more...
European Journal of Nuclear Medicine and Molecular Imaging (2013)

Fulltext@MSK | Save